GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » ROC (Joel Greenblatt) %

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) ROC (Joel Greenblatt) % : -224.61% (As of Mar. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Spectrum Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -224.61%.

The historical rank and industry rank for Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

SPPI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26338.19   Med: -3305.2   Max: -1571.45
Current: -1571.45

During the past 13 years, Spectrum Pharmaceuticals's highest ROC (Joel Greenblatt) % was -1571.45%. The lowest was -26338.19%. And the median was -3305.20%.

SPPI's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -336.59 vs SPPI: -1571.45

Spectrum Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 36.90% per year.


Spectrum Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals ROC (Joel Greenblatt) % Chart

Spectrum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26,338.19 -1,781.21 -1,598.47 -3,606.10 -3,004.29

Spectrum Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,243.79 -4,440.13 -3,980.28 -2,870.57 -224.61

Competitive Comparison of Spectrum Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Spectrum Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Spectrum Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.996 + 9.23 + 3.072) - (38.842 + 0 + 3.082)
=-16.626

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.755 + 12.862 + 2.742) - (30.002 + 0 + 8.108)
=10.249

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Spectrum Pharmaceuticals for the quarter that ended in Mar. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.252/( ( (2.17 + max(-16.626, 0)) + (2.052 + max(10.249, 0)) )/ 2 )
=-16.252/( ( 2.17 + 12.301 )/ 2 )
=-16.252/7.2355
=-224.61 %

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spectrum Pharmaceuticals  (NAS:SPPI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Spectrum Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Executives
Juhyun Lim director 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan officer: See Remarks C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan officer: Chief Legal Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga director, officer: CEO & President 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel officer: Chief Medical Officer 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas director 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson officer: EVP & Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon officer: Chief Commercial Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner director 157 TEHCNOLOGY DRIVE, IRVINE CA 92618

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPPI, HOTH

By sperokesalga sperokesalga 04-28-2023